Free Trial

InnovAge (INNV) Competitors

InnovAge logo
$3.84 +0.04 (+1.05%)
Closing price 07/25/2025 04:00 PM Eastern
Extended Trading
$3.82 -0.02 (-0.52%)
As of 07/25/2025 04:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

INNV vs. VCYT, ARDT, ADUS, PGNY, PACS, LFST, NHC, TDOC, GRAL, and VRDN

Should you be buying InnovAge stock or one of its competitors? The main competitors of InnovAge include Veracyte (VCYT), Ardent Health (ARDT), Addus HomeCare (ADUS), Progyny (PGNY), PACS Group (PACS), LifeStance Health Group (LFST), National HealthCare (NHC), Teladoc Health (TDOC), GRAIL (GRAL), and Viridian Therapeutics (VRDN). These companies are all part of the "healthcare" industry.

InnovAge vs. Its Competitors

InnovAge (NASDAQ:INNV) and Veracyte (NASDAQ:VCYT) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, dividends, profitability, media sentiment, risk and valuation.

Veracyte has lower revenue, but higher earnings than InnovAge. InnovAge is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
InnovAge$831.68M0.62-$21.34M-$0.23-16.70
Veracyte$445.76M4.44$24.14M$0.4161.59

Veracyte has a net margin of 7.13% compared to InnovAge's net margin of -3.75%. Veracyte's return on equity of 6.14% beat InnovAge's return on equity.

Company Net Margins Return on Equity Return on Assets
InnovAge-3.75% -11.91% -5.85%
Veracyte 7.13%6.14%5.60%

InnovAge has a beta of 0.51, meaning that its share price is 49% less volatile than the S&P 500. Comparatively, Veracyte has a beta of 2.07, meaning that its share price is 107% more volatile than the S&P 500.

In the previous week, Veracyte had 7 more articles in the media than InnovAge. MarketBeat recorded 9 mentions for Veracyte and 2 mentions for InnovAge. Veracyte's average media sentiment score of 1.08 beat InnovAge's score of 0.93 indicating that Veracyte is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
InnovAge
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Veracyte
4 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

12.3% of InnovAge shares are owned by institutional investors. 1.4% of InnovAge shares are owned by insiders. Comparatively, 1.4% of Veracyte shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

InnovAge presently has a consensus price target of $5.00, indicating a potential upside of 30.21%. Veracyte has a consensus price target of $40.90, indicating a potential upside of 61.98%. Given Veracyte's stronger consensus rating and higher possible upside, analysts clearly believe Veracyte is more favorable than InnovAge.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
InnovAge
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50
Veracyte
1 Sell rating(s)
1 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.70

Summary

Veracyte beats InnovAge on 13 of the 16 factors compared between the two stocks.

Get InnovAge News Delivered to You Automatically

Sign up to receive the latest news and ratings for INNV and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INNV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

INNV vs. The Competition

MetricInnovAgeMedical Services IndustryMedical SectorNASDAQ Exchange
Market Cap$513.05M$7.30B$5.69B$9.50B
Dividend YieldN/A2.84%4.58%4.01%
P/E Ratio-16.6925.2828.1020.05
Price / Sales0.6242.19432.4490.07
Price / CashN/A26.7436.2258.56
Price / Book1.889.718.665.87
Net Income-$21.34M$239.96M$3.25B$258.55M
7 Day Performance-2.29%2.92%4.23%3.74%
1 Month Performance-2.54%4.88%10.52%11.75%
1 Year Performance-39.53%15.47%34.41%18.03%

InnovAge Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
INNV
InnovAge
1.6521 of 5 stars
$3.84
+1.1%
$5.00
+30.2%
-37.6%$513.05M$831.68M-16.692,350
VCYT
Veracyte
3.6864 of 5 stars
$26.65
-1.6%
$40.90
+53.5%
+6.3%$2.09B$445.76M65.00790News Coverage
Positive News
Analyst Upgrade
Gap Up
ARDT
Ardent Health
3.5501 of 5 stars
$14.51
+2.4%
$20.67
+42.4%
-34.7%$2.08B$5.97B8.9024,900
ADUS
Addus HomeCare
4.9631 of 5 stars
$111.75
+0.7%
$142.57
+27.6%
-9.7%$2.06B$1.15B25.2349,703Positive News
PGNY
Progyny
1.0866 of 5 stars
$23.47
+1.1%
$24.09
+2.6%
-19.2%$2.01B$1.17B41.18310News Coverage
Positive News
Analyst Upgrade
PACS
PACS Group
2.4646 of 5 stars
$12.93
+1.9%
$34.29
+165.3%
-65.8%$1.97B$3.11B0.0032,433
LFST
LifeStance Health Group
2.907 of 5 stars
$4.57
+1.3%
$8.50
+86.0%
-25.3%$1.78B$1.28B-45.7010,218Analyst Forecast
NHC
National HealthCare
N/A$103.17
-0.1%
N/A-26.2%$1.60B$1.37B12.9312,400High Trading Volume
TDOC
Teladoc Health
2.8987 of 5 stars
$8.31
-0.2%
$9.65
+16.2%
-11.6%$1.46B$2.57B-1.405,500News Coverage
Upcoming Earnings
Analyst Forecast
GRAL
GRAIL
0.6526 of 5 stars
$40.18
-1.4%
$31.50
-21.6%
+154.2%$1.45B$125.60M-0.661,360Positive News
VRDN
Viridian Therapeutics
2.404 of 5 stars
$17.14
+0.6%
$37.56
+119.1%
+5.8%$1.40B$300K-4.4550News Coverage
Positive News

Related Companies and Tools


This page (NASDAQ:INNV) was last updated on 7/26/2025 by MarketBeat.com Staff
From Our Partners